Innate Pharma S.A.

NASDAQ:IPHA

Biotechnology

Healthcare
$1.03 +1.91%

+$0.03 today

Market cap
$115.05M
Beta
0.89
P/E (TTM)
-3.0
EPS (TTM)
-$0.54
52W Low $1.17High $2.63

Volume 0.50M

Average 0.07M

IPHA Interest Income

Income earned on cash, deposits, and investments held by the company.

Innate Pharma S.A.NASDAQ: IPHA

Interest Income · Q4 FY2025 · quarter ended Dec 2025

Interest income grows 6934.7% year over year

Q4 FY2025 interest income of €7.11M rose 6934.7% year over year. Over 3 fiscal years it compounded at +34.1% a year.

Context

  • Interest income amounted to 47.3% of revenue in FY2025, up 28.0 pp from a year earlier.
  • Interest income increased in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
€7.11M— QoQ
Last fiscal yearDec 2025
€1.32M-45.9% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6934.7%——
1 year-45.9%——
3-year CAGR+34.1%——
5-year CAGR——
10-year CAGR——

Interest Income history

EUR · from the income statement

Latest · FY2025
1.32M EUR
Year-over-year change
-45.9%
4-year CAGR
+41.7%

Interest Income vs competitors

How IPHA compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -45.9% is the 6th highest of 9, against a peer median of -28.5%.
  • Interest income amounts to 47.3% of revenue for IPHA, versus a peer median of 127.0%.
IPHA Competitors
Interest Income for IPHA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$5.25M USD-28.4%——
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$3.96M USD+2.3%+32.5%221.7%
CRDFCardiff Oncology, Inc.LTM Mar 2026$2.67M USD-18.5%+25.2%508.4%
CGENCompugen Ltd.LTM Mar 2026$2.66M USD-49.0%+45.3%3.7%
MOLNMolecular Partners AGLTM Mar 2026CHF 1.48M CHF-47.8%+8.4%—
IPHAInnate Pharma S.A.FY2025€1.32M EUR-45.9%+34.1%47.3%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$1.02M USD-28.6%-12.8%32.2%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$723K USD-13.6%+128.8%—
NVCTNuvectis Pharma, Inc.LTM Mar 2026-$26K USD-103.0%+96.6%—
Peer median (excluding IPHA) —-28.5%+32.5%127.0%

Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.11M57.67M51.9M12.62M2.79M
Cost of Revenue47M51.66M56.02M51.98M0
Gross Profit(22.3M)6.01M5.62M12.62M2.79M
Gross Margin-184.1%10.4%10.8%100.0%100.0%
Research & Development47M51.66M56.02M51.98M43.62M
Selling, General & Admin25.52M14.47M11.75M11.93M11M
Operating Expenses25.52M63.44M18.29M64.2M56.21M
Depreciation & Amortization4.6M45.41M5.09M1.99M5.09M
EBITDA(43.23M)(12.28M)(1.84M)(46.91M)(43.65M)
EBITDA Margin-356.9%-21.3%-3.5%-371.7%-1566.1%
Operating Income(47.83M)(57.43M)(12.67M)(51.58M)(53.43M)
Operating Margin-394.9%-99.6%-24.4%-408.6%-1916.9%
Interest Income327K546K3.18M2.44M1.32M
Interest Expense312K288K640K566K440K
Other Income / Expenses2.35M(547K)5.1M2.1M4.25M
Income Before Tax(45.48M)(57.97M)(7.57M)(49.47M)(49.18M)
Pre-Tax Margin-375.5%-100.5%-14.6%-392.0%-1764.5%
Income Tax Expense00000
Net Income(52.81M)(58.1M)(7.57M)(49.47M)(49.18M)
Net Margin-436.0%-100.7%-14.6%-392.0%-1764.5%
EPS (Basic)(0.57)(0.73)(0.09)(0.61)(0.53)
EPS (Diluted)(0.57)(0.73)(0.09)(0.61)(0.53)
Weighted Avg Shares79.54M79.59M84.11M81.05M89.42M
Weighted Avg Shares (Diluted)79.54M79.64M84.11M81.05M89.42M

Innate Pharma S.A.

NASDAQ:IPHA

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.